Cabozantinib in combination with atezolizumab (anti-PD-L1) has been studied in a randomized phase III trial (NCT03755791) comparing it with sorafenib in patients without prior systemic therapy for advanced HCC (Kelley et al., 2022). This evidence concerns the gene CD274 and hepatocellular carcinoma.